Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. All participants will be in listen-only mode.
Kymera Therapeutics Inc. (KYMR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,995,929 | $283,787,320 | +1% | 2.94% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,161,801 | $244,308,041 | 7.14% | |
| 3. | VenBio Select Advisor Kurt Von Emster | 4,500,000 | $212,985,000 | +16% | 3.1% |
| 4. | Redmile Group Jeremy Green | 1,393,256 | $65,942,806 | -12% | 3.88% |
| 5. | Driehaus Capital Richard Driehaus | 1,328,703 | $62,887,513 | +495% | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.41 | 1 | 5,516,986 | 2024-08-20 | Filing | ||
| $14.07 | 10,106 | Director, Other | 294,632 | 2023-11-03 | Filing | |
| $14.07 | 83,708 | Director, Other | 2,104,075 | 2023-11-03 | Filing | |
| $14.07 | 103,885 | Director, Other | 2,656,191 | 2023-11-03 | Filing | |
| $11.64 | 26,772 | Director, Other | 284,526 | 2023-11-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.00 | 2,500 | 0 | 2024-12-02 | Filing | ||
| $48.75 | 7,150 | 0 | 2024-09-17 | Filing | ||
| $47.75 | 6,350 | 7,150 | 2024-09-17 | Filing | ||
| $49.10 | 5,000 | 0 | 2024-08-26 | Filing | ||
| $46.10 | 9,864 | 95,470 | 2024-07-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,858,262 | $149,151,351 | 17.76% | |
| 2. | 4,815,558 | $122,604,107 | 0.02% | |
| 3. | 3,997,564 | $101,777,980 | 0% | |
| 4. | 3,566,611 | $90,805,915 | 0% | |
| 5. | 1,894,279 | $48,228,343 | 0% |
News See All
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Second Quarter 2024 Results Call. [Operator Instructions] Please note, this event is being recorded.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44.
12 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the 12 most promising cancer stocks according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2023 Results Call. [Operator Instructions]. Please note that this event is being recorded.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2023 Earnings Call Transcript
Bruce Jacobs: Good morning everyone and welcome to the Kymera Therapeutics quarterly conference call.
12 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Kymera Therapeutics First Quarter 2023 Earnings Conference Call [Operator Instructions]. Please note that this event is being recorded today.
12 Small-Cap Stocks With Insider Buying
Insider buying refers to a company's officers, directors, or major shareholders purchasing shares of their own company's stock.